查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1566981

长春西汀市场：依产品类型、通路划分：2024-2033 年全球机会分析与产业预测

Vinpocetine Market By Product Type (Tablet, Injection) , By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

长春西汀市场

2023年长春西汀市值为2亿美元，预计2024年至2033年复合年增长率为3.5%，到2033年将达3亿美元。

长春西汀是一种合成化学品，类似于从长春花植物中提取的天然化合物。这种化合物是一种多促效剂，用于治疗多种病症和疾病，包括头部外伤、中风、帕金森氏症期间的失智症、与老龄化相关的记忆力衰退和阿兹海默症。长春西汀的主要作用机转是促进脑血流量，进而改善大脑的营养和氧气供应。由于其出色的安全性，这种化学物质现在以食品补充剂的形式提供，以增强认知和记忆力。

认知障碍的盛行率不断上升，特别是由于老年人口的迅速增加，正在显着推动长春西汀市场的成长。此外，随着及时预防神经退化性疾病意识的增强，越来越多的人开始服用膳食食品作为预防措施，从而增加了对长春西汀的需求。营养食品的激增显着增加了市场的成长。目前有一个研究趋势是将长春西汀用于认知支持以外的目的。该化学物质正在测试用于治疗动脉粥状硬化和肺纤维化中肺泡上皮细胞损伤等多种疾病。这种应用的扩展预计将为市场开拓带来新的细分市场。

然而，由于其分类和功效，这种化学物质在多个国家面临各种监管障碍，这限制了市场的广泛成长。此外，还有几种治疗阿兹海默症和失智症的潜在替代药物正在阻碍市场开拓。例如，美国食品药物管理局最近核准了新药lecanemab，一种抗淀粉样蛋白单株抗体，用于治疗痴呆失智症。该药物透过与淀粉样蛋白斑块（失智症的标誌）结合，专门针对失智症的易感性。各种研究都提出了lecanemab的功效，这使其成为长春西汀市场扩张的挑战。

按部门审查

长春西汀市场分为产品类型、通路和地区。依产品类型划分，市场分为锭剂和注射剂。依销售管道可分为零售药局、医院药局、网路药局。从区域来看，分析涵盖北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

从产品类型来看，锭剂细分市场将在 2023 年占据较高的市场。

从分销通路来看，2023年零售药市场占有率较高。

从地区来看，北美在长春西汀市场占据主导地位。

可以使用此报告进行客製化（需要额外费用和时间表）

  • 新产品开发/主要企业产品矩阵
  • 监管指引
  • 根据客户兴趣新增其他公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测
  • 扩大公司简介列表
  • 历史市场资料
  • 主要参与企业的详细资料（Excel格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章长春西汀市场：依产品类型

  • 市场概况
  • 锭剂
  • 注射

第五章长春西汀市场：依通路划分

  • 市场概况
  • 零售药房
  • 医院药房
  • 网路药房

第六章 长春西汀市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国长春西汀市场
    • 加拿大长春西汀市场
    • 墨西哥长春西汀市场
  • 欧洲
    • 主要市场趋势和机会
    • 德国长春西汀市场
    • 法国长春西汀市场
    • 英国长春西汀市场
    • 义大利长春西汀市场
    • 西班牙长春西汀市场
    • 其他欧洲长春西汀市场
  • 亚太地区
    • 主要市场趋势和机会
    • 日本长春西汀市场
    • 中国长春西汀市场
    • 澳洲长春西汀市场
    • 印度长春西汀市场
    • 韩国长春西汀市场
    • 其他亚太地区长春西汀市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西长春西汀市场
    • 沙乌地阿拉伯的长春西汀市场
    • 南非长春西汀市场
    • 其他拉丁美洲/中东/非洲长春西汀市场

第七章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • Northeast Pharmaceutical Group Co., Ltd.
  • COVEX
  • Runhong
  • Liaoning Zhiying
  • Sun Pharmaceuticals Industries Ltd
  • Welman
  • Micro Labs Ltd
  • Gedeon Richter Plc.
简介目录
Product Code: A324539

Vinpocetine Market

The vinpocetine market was valued at $0.2 billion in 2023 and is projected to reach $0.3 billion by 2033, growing at a CAGR of 3.5% from 2024 to 2033.

Vinpocetine is a synthetic chemical that holds resemblance with a natural compound derived from the plant Vinca minor. The compound is a multi-action agent used to treat various conditions and diseases, including head injuries, stroke, dementia during Parkinson's disease, age-related memory loss, and Alzheimer's disease. The primary action mechanism of vinpocetine involves the enhancement of cerebral blood flow, resulting in improved nutrient and oxygen delivery to the brain. Owing to its remarkable safety profile, the chemical has been made available in the form of dietary supplement for enhanced cognition and memory.

Increase in the prevalence of cognitive disorders, particularly due to exponential growth in the elderly population has significantly driven the growth of the vinpocetine market. In addition, with rising awareness regarding the timely prevention of neurodegenerative diseases, individuals are beginning the consumption of dietary supplements as a precautionary measure, thereby boosting the demand for vinpocetine. The expanding landscape of dietary supplements augments the growth of the market notably. Currently, explorations regarding the applications of vinpocetine beyond its cognitive support are trending. The chemical has been tested for the treatment of diverse conditions such as atherosclerosis and injured alveolar epithelial cells in pulmonary fibrosis. Such expansion of applications is projected to present new segments for market development.

However, the chemical faces different regulatory hurdles in several countries owing to its classification and efficacy, which restrains the widespread growth of the market. Furthermore, several alternative and competent alternatives are available for the treatment of Alzheimer's and dementia, hampering market development. For instance, the U.S. Food and Drug Administration and recently approved the efficacy of a novel drug-lecanemab-an anti-amyloid monoclonal antibody, for the treatment of dementia. The drug particularly targets the elementary causes of the disease by binding to amyloid-beta plaques, the hallmark of the disease. Different studies have advocated for the effectiveness of lecanemab, presenting challenges for the expansion of the vinpocetine market.

Segment Review

The vinpocetine market is segmented into product type, distribution channel, and region. On the basis of product type, the market is bifurcated into tablet and injection. As per distribution channel, it is divided into retail pharmacies, hospital pharmacies, and online pharmacies. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of product type, the tablet segment acquired a high stake in the market in 2023.

As per distribution channel, the retail pharmacies segment accounted for a high market share in 2023.

Region wise, North America holds a dominant position in the vinpocetine market.

Competition Analysis

The leading players operating in the global vinpocetine market include Northeast Pharmaceutical Group Co., Ltd., Gedeon Richter, COVEX, Runhong, Liaoning Zhiying, Sun Pharmaceuticals Industries Ltd, Welman, and Micro Labs Ltd. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships, to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • New Product Development/ Product Matrix of Key Players
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Tablet
  • Injection

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Northeast Pharmaceutical Group Co., Ltd.
    • COVEX
    • Runhong
    • Liaoning Zhiying
    • Sun Pharmaceuticals Industries Ltd
    • Welman
    • Micro Labs Ltd
    • Gedeon Richter Plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: VINPOCETINE MARKET, BY PRODUCT TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product Type
  • 4.2. Tablet
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Injection
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: VINPOCETINE MARKET, BY DISTRIBUTION CHANNEL

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Distribution Channel
  • 5.2. Retail Pharmacies
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Hospital Pharmacies
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Online Pharmacies
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: VINPOCETINE MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product Type
    • 6.2.3. Market Size and Forecast, By Distribution Channel
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Vinpocetine Market
      • 6.2.5.1. Market Size and Forecast, By Product Type
      • 6.2.5.2. Market Size and Forecast, By Distribution Channel
    • 6.2.6. Canada Vinpocetine Market
      • 6.2.6.1. Market Size and Forecast, By Product Type
      • 6.2.6.2. Market Size and Forecast, By Distribution Channel
    • 6.2.7. Mexico Vinpocetine Market
      • 6.2.7.1. Market Size and Forecast, By Product Type
      • 6.2.7.2. Market Size and Forecast, By Distribution Channel
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product Type
    • 6.3.3. Market Size and Forecast, By Distribution Channel
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Vinpocetine Market
      • 6.3.5.1. Market Size and Forecast, By Product Type
      • 6.3.5.2. Market Size and Forecast, By Distribution Channel
    • 6.3.6. France Vinpocetine Market
      • 6.3.6.1. Market Size and Forecast, By Product Type
      • 6.3.6.2. Market Size and Forecast, By Distribution Channel
    • 6.3.7. UK Vinpocetine Market
      • 6.3.7.1. Market Size and Forecast, By Product Type
      • 6.3.7.2. Market Size and Forecast, By Distribution Channel
    • 6.3.8. Italy Vinpocetine Market
      • 6.3.8.1. Market Size and Forecast, By Product Type
      • 6.3.8.2. Market Size and Forecast, By Distribution Channel
    • 6.3.9. Spain Vinpocetine Market
      • 6.3.9.1. Market Size and Forecast, By Product Type
      • 6.3.9.2. Market Size and Forecast, By Distribution Channel
    • 6.3.10. Rest of Europe Vinpocetine Market
      • 6.3.10.1. Market Size and Forecast, By Product Type
      • 6.3.10.2. Market Size and Forecast, By Distribution Channel
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product Type
    • 6.4.3. Market Size and Forecast, By Distribution Channel
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Vinpocetine Market
      • 6.4.5.1. Market Size and Forecast, By Product Type
      • 6.4.5.2. Market Size and Forecast, By Distribution Channel
    • 6.4.6. China Vinpocetine Market
      • 6.4.6.1. Market Size and Forecast, By Product Type
      • 6.4.6.2. Market Size and Forecast, By Distribution Channel
    • 6.4.7. Australia Vinpocetine Market
      • 6.4.7.1. Market Size and Forecast, By Product Type
      • 6.4.7.2. Market Size and Forecast, By Distribution Channel
    • 6.4.8. India Vinpocetine Market
      • 6.4.8.1. Market Size and Forecast, By Product Type
      • 6.4.8.2. Market Size and Forecast, By Distribution Channel
    • 6.4.9. South Korea Vinpocetine Market
      • 6.4.9.1. Market Size and Forecast, By Product Type
      • 6.4.9.2. Market Size and Forecast, By Distribution Channel
    • 6.4.10. Rest of Asia-Pacific Vinpocetine Market
      • 6.4.10.1. Market Size and Forecast, By Product Type
      • 6.4.10.2. Market Size and Forecast, By Distribution Channel
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product Type
    • 6.5.3. Market Size and Forecast, By Distribution Channel
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Vinpocetine Market
      • 6.5.5.1. Market Size and Forecast, By Product Type
      • 6.5.5.2. Market Size and Forecast, By Distribution Channel
    • 6.5.6. Saudi Arabia Vinpocetine Market
      • 6.5.6.1. Market Size and Forecast, By Product Type
      • 6.5.6.2. Market Size and Forecast, By Distribution Channel
    • 6.5.7. South Africa Vinpocetine Market
      • 6.5.7.1. Market Size and Forecast, By Product Type
      • 6.5.7.2. Market Size and Forecast, By Distribution Channel
    • 6.5.8. Rest of LAMEA Vinpocetine Market
      • 6.5.8.1. Market Size and Forecast, By Product Type
      • 6.5.8.2. Market Size and Forecast, By Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Northeast Pharmaceutical Group Co., Ltd.
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. COVEX
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Runhong
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Liaoning Zhiying
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Sun Pharmaceuticals Industries Ltd
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Welman
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Micro Labs Ltd
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Gedeon Richter Plc.
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments